Answers are grounded in this paper and cite their sources.
There was no difference in the combined outcome of clinical failure or 90-day recurrence between fidaxomicin and oral vancomycin in the treatment of first or second recurrent CDI.
No takes yet. Share an insight, caveat, or question.
Tieu et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: